Search results for abx831373

Navicixizumab, Abbexa, abx831373

Navicixizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting DLL4/VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).